vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and TRUPANION, INC. (TRUP). Click either name above to swap in a different company.
TRUPANION, INC. is the larger business by last-quarter revenue ($376.9M vs $191.2M, roughly 2.0× Axsome Therapeutics, Inc.). On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (57.4% vs 11.7%). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (48.1% CAGR vs 11.0%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
TRUPANION, INC.TRUPEarnings & Financial Report
Trupanion, Inc. is a pet insurance provider headquartered in Seattle, Washington. Established in 1998, Trupanion operates across the United States, Canada, Australia, and Puerto Rico. The company offers coverage for pets and is self-underwritten by the American Pet Insurance Company (APIC).
AXSM vs TRUP — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $191.2M | $376.9M |
| Net Profit | — | — |
| Gross Margin | — | 17.3% |
| Operating Margin | -33.1% | 1.9% |
| Net Margin | — | — |
| Revenue YoY | 57.4% | 11.7% |
| Net Profit YoY | — | — |
| EPS (diluted) | — | $0.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $191.2M | — | ||
| Q4 25 | $196.0M | $376.9M | ||
| Q3 25 | $171.0M | $366.9M | ||
| Q2 25 | $150.0M | $353.6M | ||
| Q1 25 | $121.5M | $342.0M | ||
| Q4 24 | $118.8M | $337.3M | ||
| Q3 24 | $104.8M | $327.5M | ||
| Q2 24 | $87.2M | $314.8M |
| Q1 26 | — | — | ||
| Q4 25 | $-28.6M | — | ||
| Q3 25 | $-47.2M | — | ||
| Q2 25 | $-48.0M | — | ||
| Q1 25 | $-59.4M | — | ||
| Q4 24 | $-74.9M | — | ||
| Q3 24 | $-64.6M | — | ||
| Q2 24 | $-79.3M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 17.3% | ||
| Q3 25 | — | 16.4% | ||
| Q2 25 | — | 15.5% | ||
| Q1 25 | — | 14.9% | ||
| Q4 24 | — | 15.7% | ||
| Q3 24 | — | 15.1% | ||
| Q2 24 | — | 12.8% |
| Q1 26 | -33.1% | — | ||
| Q4 25 | -13.8% | 1.9% | ||
| Q3 25 | -27.0% | 1.6% | ||
| Q2 25 | -24.5% | 0.7% | ||
| Q1 25 | -46.9% | -0.4% | ||
| Q4 24 | -61.1% | 0.1% | ||
| Q3 24 | -59.8% | 0.5% | ||
| Q2 24 | -89.5% | -1.7% |
| Q1 26 | — | — | ||
| Q4 25 | -14.6% | — | ||
| Q3 25 | -27.6% | — | ||
| Q2 25 | -32.0% | — | ||
| Q1 25 | -48.9% | — | ||
| Q4 24 | -63.1% | — | ||
| Q3 24 | -61.7% | — | ||
| Q2 24 | -91.0% | — |
| Q1 26 | — | — | ||
| Q4 25 | $-0.55 | $0.13 | ||
| Q3 25 | $-0.94 | $0.13 | ||
| Q2 25 | $-0.97 | $0.22 | ||
| Q1 25 | $-1.22 | $-0.03 | ||
| Q4 24 | $-1.54 | $0.04 | ||
| Q3 24 | $-1.34 | $0.03 | ||
| Q2 24 | $-1.67 | $-0.14 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $305.1M | $370.7M |
| Total DebtLower is stronger | $70.0M | $101.8M |
| Stockholders' EquityBook value | — | $383.9M |
| Total Assets | $713.6M | $915.0M |
| Debt / EquityLower = less leverage | — | 0.27× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $305.1M | — | ||
| Q4 25 | $322.9M | $370.7M | ||
| Q3 25 | $325.3M | $348.5M | ||
| Q2 25 | $303.0M | $319.6M | ||
| Q1 25 | $300.9M | $321.8M | ||
| Q4 24 | $315.4M | $307.4M | ||
| Q3 24 | $327.3M | $293.1M | ||
| Q2 24 | $315.7M | $277.2M |
| Q1 26 | $70.0M | — | ||
| Q4 25 | — | $101.8M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $127.5M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | $88.3M | $383.9M | ||
| Q3 25 | $73.7M | $368.6M | ||
| Q2 25 | $73.1M | $355.5M | ||
| Q1 25 | $53.2M | $333.7M | ||
| Q4 24 | $57.0M | $323.3M | ||
| Q3 24 | $92.9M | $320.2M | ||
| Q2 24 | $102.9M | $305.8M |
| Q1 26 | $713.6M | — | ||
| Q4 25 | $689.8M | $915.0M | ||
| Q3 25 | $669.3M | $880.2M | ||
| Q2 25 | $639.8M | $847.8M | ||
| Q1 25 | $596.7M | $837.2M | ||
| Q4 24 | $568.5M | $806.9M | ||
| Q3 24 | $561.5M | $816.1M | ||
| Q2 24 | $548.2M | $795.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.27× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.39× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $29.3M |
| Free Cash FlowOCF − Capex | — | $25.3M |
| FCF MarginFCF / Revenue | — | 6.7% |
| Capex IntensityCapex / Revenue | — | 1.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $75.4M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $29.3M | ||
| Q3 25 | $1.0M | $29.2M | ||
| Q2 25 | $-32.4M | $15.0M | ||
| Q1 25 | $-43.4M | $16.0M | ||
| Q4 24 | $-26.2M | $23.7M | ||
| Q3 24 | $-18.6M | $15.3M | ||
| Q2 24 | $-30.1M | $6.9M |
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $25.3M | ||
| Q3 25 | $988.0K | $23.9M | ||
| Q2 25 | $-32.4M | $12.0M | ||
| Q1 25 | $-43.7M | $14.0M | ||
| Q4 24 | $-26.2M | $21.8M | ||
| Q3 24 | $-18.7M | $13.4M | ||
| Q2 24 | $-30.2M | $4.0M |
| Q1 26 | — | — | ||
| Q4 25 | -9.6% | 6.7% | ||
| Q3 25 | 0.6% | 6.5% | ||
| Q2 25 | -21.6% | 3.4% | ||
| Q1 25 | -36.0% | 4.1% | ||
| Q4 24 | -22.1% | 6.5% | ||
| Q3 24 | -17.9% | 4.1% | ||
| Q2 24 | -34.6% | 1.3% |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 1.0% | ||
| Q3 25 | 0.0% | 1.4% | ||
| Q2 25 | 0.0% | 0.8% | ||
| Q1 25 | 0.3% | 0.6% | ||
| Q4 24 | 0.0% | 0.6% | ||
| Q3 24 | 0.1% | 0.6% | ||
| Q2 24 | 0.1% | 0.9% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
| Product sales, net | $189.4M | 99% |
| Royalty revenue and milestone revenue | $1.8M | 1% |
TRUP
| Subscriptionbusiness | $261.4M | 69% |
| Other | $115.4M | 31% |
